Literature DB >> 23086624

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Elias Jabbour, Van Morris, Hagop Kantarjian, Cameron C Yin, Elizabeth Burton, Jorge Cortes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23086624      PMCID： PMC4195445          DOI： 10.1182/blood-2012-04-424192

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

Review 1.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Authors:  Simona Soverini; Andreas Hochhaus; Franck E Nicolini; Franz Gruber; Thoralf Lange; Giuseppe Saglio; Fabrizio Pane; Martin C Müller; Thomas Ernst; Gianantonio Rosti; Kimmo Porkka; Michele Baccarani; Nicholas C P Cross; Giovanni Martinelli
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

2.  ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Giovanni Martinelli; Gianantonio Rosti; Simona Bassi; Marilina Amabile; Angela Poerio; Barbara Giannini; Elena Trabacchi; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Antonio de Vivo; Daniela Cilloni; Barbara Izzo; Milena Fava; Elisabetta Abruzzese; Daniele Alberti; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

3.  Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Authors:  E Jabbour; H Kantarjian; D Jones; M Talpaz; N Bekele; S O'Brien; X Zhou; R Luthra; G Garcia-Manero; F Giles; M B Rios; S Verstovsek; J Cortes
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

4.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

5.  Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

Authors:  Jorge Cortes; Elias Jabbour; Hagop Kantarjian; C Cameron Yin; Jianqin Shan; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Megan Breeden; Nubia Reeves; William G Wierda; Dan Jones
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

6.  Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Authors:  Sara Redaelli; Rocco Piazza; Roberta Rostagno; Vera Magistroni; Pietro Perini; Manuela Marega; Carlo Gambacorti-Passerini; Frank Boschelli
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
  7 in total
  6 in total

1.  Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Authors:  Boyang Zhao; Joseph C Sedlak; Raja Srinivas; Pau Creixell; Justin R Pritchard; Bruce Tidor; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cell       Date:  2016-02-25       Impact factor: 41.582

2.  Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).

Authors:  Jiaxin Wu; Aoli Wang; Xixiang Li; Cheng Chen; Ziping Qi; Chen Hu; Wenliang Wang; Hong Wu; Tao Huang; Ming Zhao; Wenchao Wang; Zhenquan Hu; Qingwang Liu; Beilei Wang; Li Wang; Lili Li; Jian Ge; Tao Ren; Ruixiang Xia; Jing Liu; Qingsong Liu
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

Review 3.  Current developments in molecular monitoring in chronic myeloid leukemia.

Authors:  Justine Ellen Marum; Susan Branford
Journal:  Ther Adv Hematol       Date:  2016-07-15

4.  Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.

Authors:  Kendra Sweet; Najla H Al Ali; Samir M Dalia; Rami S Komrokji; Robert M Crescentini; Sara Tinsley; Jeffrey E Lancet; Peter R Papenhausen; Ling Zhang; Javier Pinilla-Ibarz
Journal:  Int J Hematol       Date:  2014-10-04       Impact factor: 2.490

5.  Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.

Authors:  Radowan Elnair; Ahmed Galal
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

6.  Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.

Authors:  Teresa Kaserer; Julian Blagg
Journal:  Cell Chem Biol       Date:  2018-08-23       Impact factor: 8.116
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.